精伦电子(600355.SH)公告称，公司2024年度经审计的利润总额、 净利润、扣除非经常性损益后的净利 润三者均为负值，且扣除与主营业务无关的业务收入和不具备商业实质的收入后的 营业收入低于3亿 元，触及《上海证券交易所股票上市规则》第9.3.2条第一款第（一）项规定，公司股票将被实施 退市 风险警示。公司股票于4月28日 停牌1天，4月29日起实施退市风险警示，股票简称由"精伦电子"变更 为"*ST精伦"。实施退市风险警示后公司股票价格的日涨跌幅限制为5%。 ...

华嵘控股（600421）公告，公司2024年度经审计的扣除非经常性损益前后的净利润均为负值，且扣除与 主营业务无关的业务收入和不具备商业实质的收入后的营业收入低于3亿元。公司股票将于2025年4月28 日停牌1天，自2025年4月29日开市起复牌并实施退市风险警示，实施退市风险警示后，公司股票将在风 险警示板交易，股票价格的日涨跌幅限制为5%。 ...

中国经济网北京4月25日讯亚振家居（603389）(603389.SH)今日收报6.58元，跌幅5.19%。 亚振家居昨晚发布关于筹划控制权变更事项复牌的公告。因亚振家居控股股东上海亚振投资有限公司(以下简称"控股股东"或"亚振投资")筹 划控制权变更事项已取得进一步进展，经公司向上海证券交易所申请，公司股票(证券代码：603389，证券简称：亚振家居)将于2025年4月 25日(星期五)开市起复牌。 公司于2025年4月17日收到公司控股股东的通知，控股股东正在筹划公司股份协议转让事宜，该事项可能导致公司控制权发生变更。鉴于上 述事项正在洽谈当中，尚存在不确定性，为保证公平信息披露，维护投资者利益，避免造成公司股价异常波动，根据《上海证券交易所股 票上市规则》《上海证券交易所上市公司自律监管指引第4号——停复牌》等有关规定，经公司向上海证券交易所申请，公司股票(证券代 码：603389，证券简称：亚振家居)于2025年4月18日(星期五)开市起停牌。 同时，亚振投资及其一致行动人浦振投资、恩源投资不可撤销地承诺，自本次股份转让完成之日至本次要约收购完成之日止，亚振投资及 其一致行动人浦振投资、恩源投资放弃各 ...

2025年4月22日，A股上市公司华嵘控股（600421）发布2024年年度业绩预亏更正公告，公司预计2024 年年度实现利润总额为-120万元至-180万元，与此前预计的-70万元至-100万元相比，预亏额度进一步扩 大。这一消息无疑给本就承压的华嵘控股股价带来更大压力，公司股票也面临被实施退市风险警示的风 险。 华嵘控股在公告中表示，随着年报审计工作的推进，公司与年审会计师沟通后，对公司2024年度业绩预 告进行了更正。本次业绩预告更正的主要原因系公司个别客户经营恶化，应收账款收回可能性降低，公 司对该部分客户的应收账款追加计提了坏账准备，导致公司利润总额减少。 一旦公司股票被实施退市风险警示，将在股票简称前加上"*ST"标识，这不仅会影响公司的市场形象， 还可能引发投资者的抛售情绪，进一步加剧公司的股价下跌压力。 注：本文结合AI生成，文中观点不构成投资建议，仅供参考。市场有风险，投资需谨慎。 责任编辑：AI观察员 从财务数据来看，华嵘控股在2024年度的经营压力显著增大。公司预计2024年年度实现营业收入1.1亿 元至1.2亿元，虽然与上一年度相比可能变化不大，但扣除与主营业务无关的业务收入和不具备商 ...

Core Viewpoint - A-share listed company Chengchang Technology (001270) faces unprecedented operational challenges and market pressure, leading to a formal delisting risk warning and a change in stock abbreviation to "*ST Chengchang" starting April 24, 2025 [1] Financial Performance - In 2024, Chengchang Technology reported an operating revenue of 212 million yuan, a year-on-year decline of 26.38% [1] - The company recorded a net profit attributable to shareholders of -31.12 million yuan, showing a significant year-on-year decrease [1] - After excluding non-recurring gains and losses, the net profit loss reached 43.61 million yuan [1] Business Challenges - The company's main business involves the research, production, sales, and technical services of microwave and millimeter-wave analog phased array T/R chips [1] - The sharp decline in performance reflects various challenges faced during operations, including long production cycles of downstream equipment and delays in project approvals, which severely impacted revenue recognition and profit realization [1] R&D and Financial Management - Chengchang Technology has been increasing its R&D investment to maintain technological leadership and market competitiveness, which has negatively impacted revenue and net profit [2] - The increase in credit impairment losses on accounts receivable has also significantly contributed to the decline in net profit [2] Strategic Response - In response to the delisting risk warning, Chengchang Technology plans to take proactive measures to address its operational difficulties [2] - The company aims to enhance product quality and technical standards while strengthening communication and cooperation with customers to accelerate product delivery and acceptance [2] - Additionally, the company will focus on improving internal management and risk control, optimizing accounts receivable management, and exploring new business areas and market opportunities for profit growth [2]

绿康生化（002868）公告，预计2024年期末净资产为-2300万元，归属上市公司股东的净利润为亏损 4.35亿元–3.85亿元。根据《深圳证券交易所股票上市规则》规定，公司股票交易将在2024年年度报告披 露后被实施退市风险警示(*ST)。此外，公司股票也可能被实施其他风险警示(ST)，因公司最近连续三 个会计年度扣除非经常性损益前后净利润均为负值，且最近一年审计报告显示公司持续经营能力存在不 确定性。 ...

Core Viewpoint - Nanhua Biological (000504.SZ) significantly revised its 2024 annual performance forecast from a profit of 12.5 million to 15.5 million yuan to a loss of 19 million to 21 million yuan, triggering delisting risk warning conditions [1] Group 1: Performance Revision - The company’s 2024 net profit and net profit after deducting non-recurring gains and losses are both negative, with operating revenue below 300 million yuan, leading to a "*ST" designation for its stock [1] - The revision was attributed to return risks primarily related to the sales of the company's beauty products, as prior profit announcements were made before a comprehensive audit [5] Group 2: Business Transformation - Nanhua Biological has been transitioning towards beauty and anti-aging sectors, which are key areas of its recent business strategy, while previously being involved in real estate, media, biomedicine, and energy-saving industries [5] - The company has faced delisting risk warnings multiple times in the past due to consecutive years of losses, specifically in 2010, 2013, 2016, and 2019 [5] Group 3: Management and Control - The frequent changes in the company's business focus are linked to changes in its controlling shareholders, although the company asserts that there are no internal management issues or control deficiencies [5]

4月22日，南华生物开盘即一字跌停，报8.11元，总市值为26.76亿元。 | 9.07 | | | | --- | --- | --- | | 9.01 | | | | 8.95 | | | | 8,88 | | | | 8.82 | | | | 8.75 | | | | 8.69 | | | | 8.62 | | | | 8,56 | | | | 8.50 | | | | 8.43 | | | | 8,37 | | | | 8.30 | | | | 8.24 | | | | 8.17 | | | | 8,11 | | | | 04/22 | 11:00 | 11:30 | 这一股价变动主要源于公司前一日晚间发布的业绩预告修正公告，即2024年归属于上市公司股东的净利润由预盈1250万–1550万元修正为预亏1900万–2100万 元。 业绩大变脸 | 项目 | 本报告期 | | 上年同期 | 是否修 | | --- | --- | --- | --- | --- | | | 原预计 | 最新预计 | | 正 | | 归属于上市公司 | 盈利: 1,250 万元 | 亏损:1,900 万 元 -2,100 ...

*ST中利（002309）公告，公司2024年度财务报告显示净资产为正值，营业收入23.58亿元，已触发撤销 退市风险警示条件。公司因2023年度净资产为负值及财务报告内部控制否定意见而触及的退市风险警示 和其他风险警示情形已消除。公司已向深圳证券交易所申请撤销相应警示，但申请仍需深交所批准，存 在不确定性。此外，由于公司被中国证监会作出行政处罚决定书未满12个月，仍触及其他风险警示，股 票交易日涨跌幅限制继续为5%。投资者需关注相关风险。 ...

Core Viewpoint - ST Tianlong's 2024 annual report reveals significant financial distress, with a sharp decline in revenue and an increase in losses, raising concerns about its operational viability and future prospects [1][4][5]. Financial Performance - The company reported a total revenue of 161 million yuan in 2024, a substantial decrease of 56.26% compared to 368 million yuan in 2023 [4]. - The net profit attributable to shareholders was -27 million yuan, representing an increase in losses by 218.14% year-on-year [4]. - The non-recurring net profit also showed a loss of -27.07 million yuan, down 80.32% from the previous year [4]. - Gross profit for 2024 was 23.17 million yuan, a decline of 20.7% from 29.23 million yuan in 2023, indicating issues in cost control and project profitability [4]. Operational Challenges - Despite adding three new performance projects and renewing seven operation projects, the overall performance remains concerning, suggesting difficulties in business expansion and project execution [1][4]. - The company has faced challenges in converting its investments in the renewable energy sector into revenue growth [4]. Audit and Compliance Issues - The audited net assets for 2024 were reported as negative, and the company has recorded negative net profits for the last three accounting years, leading to a "delisting risk warning" from the Shenzhen Stock Exchange [5]. - The audit report from Zhongxinghua Accounting Firm included a paragraph highlighting significant uncertainty regarding the company's ability to continue as a going concern [5]. Asset Impairment - ST Tianlong recognized asset impairment provisions totaling 16.45 million yuan in 2024, which further pressured its financial performance [6]. - The reasons for asset impairment may relate to underperformance in expected returns from renewable energy projects, despite some projects meeting operational targets [6]. - The frequent occurrence of asset impairment indicates deficiencies in project selection and risk management [6].